Table 1.
Characteristic | 2 hour cryotherapy (n = 73) |
6 hour cryotherapy (n = 73) |
|
---|---|---|---|
Age | |||
Mean (sd) | 58.3 (8.1) | 58.1 (7.2) | |
Median (min – max) | 60 (38 – 71) | 59 (35 – 72) | |
< 60 | 35 (48.0) | 39 (53.4) | |
60 – 65 | 23 (31.5) | 27 (37.0) | |
> 65 | 15 (20.5) | 7 (9.6) | |
| |||
Gender | |||
Male (%) | 46 (63.0) | 44 (60.3) | |
Female (%) | 27 (37.0) | 29 (39.7) | |
| |||
Race | |||
White (%) | 66 (90.4) | 61 (83.6) | |
Other (%) | 7 (9.6) | 12 (16.4) | |
| |||
Risk group | |||
Standard (%) | 44 (60.3) | 45 (61.6) | |
Intermediate (%) | 13 (17.8) | 21 (28.8) | |
High (%) | 13 (17.8) | 6 (8.2) | |
Missing (%) | 3 (4.1) | 1 (1.4) | |
| |||
Melphalan dose | |||
140 mg/m2 (%) | 12 (16.4) | 11 (15.1) | |
200 mg/m2 (%) | 61 (83.6) | 62 (84.9) | |
| |||
CD34+ stem cell dose (106 cells/kg) | |||
Mean (sd) | 4.6 (2.2) | 4.7 (2.1) | |
Median (min – max) | 4.2 (2.0 – 15.7) | 4.1 (1.9 – 11.7) | |
| |||
Creatinine Clearance (mL/min) | |||
Mean (sd) | 87.4 (42.5) | 87.6 (40.7) | |
Median (min – max) | 85.2 (7.39 – 196.5) | 90.6 (0.2 – 168.7) | |
| |||
Hemoglobin (g/dL) | |||
Mean (sd) | 11.0 (1.7) | 10.9 (1.6) | |
Median (min – max) | 10.9 (7.1 – 14.8) | 10.9 (7.0 – 14.7) | |
| |||
Fat Free Mass (kg) | |||
Mean (sd) | 57.7 (13.3) | 58.3 (11.9) | |
Median (min – max) | 61.5 (31.3 – 81.9) | 60.0 (35.2 – 80.4) | |
| |||
SLC7A5 genotype (rs4240803) | |||
MAF (p value) | 0.31 (0.996) | 0.3 (0.908) | |
M/M (%) | 24 (32.9) | 26 (35.6) | |
M/m (%) | 21 (28.8) | 25 (34.2) | |
m/m (%) | 5 (6.8) | 4 (5.5) | |
Missing (%) | 23 (31.5) | 18 (24.7) |
Risk groups were defined by cytogenetic analysis of diagnostic bone marrow samples as defined by Mikhael and colleagues (19). For SLC7A5 genotyping, MAF, minor allele frequency; M, major allele; m, minor allele; Two-tailed χ2 tests were used to analyze the differences between the actual and predicted (Hardy-Weinberg equilibrium) genotype frequency, and the p-values for these are presented.